<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03009318</url>
  </required_header>
  <id_info>
    <org_study_id>81171295</org_study_id>
    <nct_id>NCT03009318</nct_id>
  </id_info>
  <brief_title>Combination of MRS and 11C-methionine PET/CT in the Diagnosis of Glioma</brief_title>
  <official_title>Combination of Magnetic Resonance Spectroscopy and 11C-methionine PET/CT in the Diagnosis of Non-enhancing Supratentorial Glioma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRS and 11C-MET PET/CT are commonly used as supplementary imaging techniques for the
      differential diagnosis of non-enhancing supratentorial gliomas. However, both techniques
      have limitations leading to misdiagnosis; therefore, the investigators attempted to combine
      these two metabolic imaging tools to evaluate whether the combination of MRS and 11C-MET
      PET/CT can increase the sensitivity of the radiological diagnosis of non-enhancing
      supratentorial gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral gliomas account for 29% of all primary brain tumors and 81% of malignant brain
      tumors. Structural imaging with MRI is the most commonly accepted method for obtaining
      radiological information leading to the diagnosis. However, most low-grade gliomas (LGGs),
      and even some high-grade gliomas (HGGs), are not enhanced in MRI-contrast imaging. Despite
      applying supplementary MRI sequences such as T2 FLAIR and DWI, non-enhancing gliomas remain
      difficult to differentiate from nontumorous lesions, including those arising from
      demyelination, inflammation, encephalomalacia and gliosis.

      To overcome the deficiencies of structural imaging, metabolic imaging is used as a
      complementary imaging technique for the diagnosis of brain tumors. MRS and PET/CT are two
      types of metabolic imaging tools that exhibit promising utility in brain tumor imaging.

      Previous research revealed that the maximum Cho/NAA index (CNImax) threshold of 2.0
      predicted tumor infiltration with probabilities of 90% in HGGs and 87% in LGGs. However,
      when tumors are located near convex or ventricular systems, scalp fat and skull lipids could
      affect the quality of the MRS imaging. Moreover, the elevation of CNImax can be detected in
      other intracranial tumors such as lymphoma and some non-neoplastic lesions such as those
      caused by demyelination, encephalitis and vasculitis.

      PET/CT also allows the noninvasive study of various biologic processes in tumor tissue.
      Among various types of radiotracers synthetized to detect brain tumors, 11C-MET is a
      well-established PET/CT radiotracer for brain tumor detection and delineation. Because of
      its comparatively low background activity in normal brain tissue, 11C-MET PET/CT
      differentiates nontumorous lesions from malignant lesions with high sensitivity and
      specificity. Though the overall sensitivity for 11C-MET PET/CT is from 76% to 100%, the
      sensitivity is lower in studies with higher proportions of non-enhancing low-grade gliomas8.

      Given the advantages and limitations of MRS and 11C-MET PET/CT, the investigators attempted
      to evaluate whether the combination of these two metabolic imaging tools can improve the
      sensitivity of the radiological diagnosis of non-enhancing supratentorial glioma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the combination of MRS and 11C-MET PET/CT</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relationship between 11C-MET PET/CT results and molecular pathogeneses</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>MRS imaging and 11C-MET PET/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each patient underwent both MRS imaging and 11C-MET PET/CT scan prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tumors are confirmed by surgery and pathology</intervention_name>
    <description>Each patient undergoes both MRS imaging and 11C-MET PET/CT scan prior to surgery. The lesion will be considered as a glioma when either MRS or 11C-MET PET/CT results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.</description>
    <arm_group_label>MRS imaging and 11C-MET PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI

          2. No surgery, chemotherapy or radiotherapy history

          3. All patients gave written informed consent.

        Exclusion Criteria:

          1. Patients with infratentorial Neoplasms

          2. Patients with enhancing supratentorial lesions

          3. Recurrent gliomas after surgery

          4. Primary gliomas with history of radiotherapy or chemotherapy

          5. History of malignant tumours at any body site

          6. Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongxiao Zhuang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital, Sudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan hospital, Fudan university</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63. doi: 10.1093/neuonc/nou223.</citation>
    <PMID>25304271</PMID>
  </reference>
  <reference>
    <citation>Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ. The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):457-79. doi: 10.1007/s11060-015-1908-9. Epub 2015 Nov 3. Review.</citation>
    <PMID>26530262</PMID>
  </reference>
  <reference>
    <citation>Wang W, Hu Y, Lu P, Li Y, Chen Y, Tian M, Yu L. Evaluation of the diagnostic performance of magnetic resonance spectroscopy in brain tumors: a systematic review and meta-analysis. PLoS One. 2014 Nov 13;9(11):e112577. doi: 10.1371/journal.pone.0112577. eCollection 2014 Nov 13. Review.</citation>
    <PMID>25393009</PMID>
  </reference>
  <reference>
    <citation>Martínez-Bisbal MC, Celda B. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging. 2009 Dec;53(6):618-30. Review.</citation>
    <PMID>20016453</PMID>
  </reference>
  <reference>
    <citation>Guo J, Yao C, Chen H, Zhuang D, Tang W, Ren G, Wang Y, Wu J, Huang F, Zhou L. The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien). 2012 Aug;154(8):1361-70; discussion 1370. doi: 10.1007/s00701-012-1418-x. Epub 2012 Jun 23.</citation>
    <PMID>22729482</PMID>
  </reference>
  <reference>
    <citation>Yamasaki F, Takayasu T, Nosaka R, Amatya VJ, Doskaliyev A, Akiyama Y, Tominaga A, Takeshima Y, Sugiyama K, Kurisu K. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma. J Neurosurg. 2015 Jun;122(6):1370-9. doi: 10.3171/2014.9.JNS14106. Epub 2015 Mar 6.</citation>
    <PMID>25748300</PMID>
  </reference>
  <reference>
    <citation>Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dinçer A, Dydak U, Emir UE, Frahm J, González RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Hüppi PS, Hurd RE, Kantarci K, Klomp DW, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjańska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJ, Ratai EM, Ross BD, Scheenen TW, Schuster C, Smith IC, Soher BJ, Tkáč I, Vigneron DB, Kauppinen RA; MRS Consensus Group.. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014 Mar;270(3):658-79. doi: 10.1148/radiol.13130531. Review.</citation>
    <PMID>24568703</PMID>
  </reference>
  <reference>
    <citation>WRENN FR Jr, GOOD ML, HANDLER P. The use of positron-emitting radioisotopes for the localization of brain tumors. Science. 1951 May 4;113(2940):525-7.</citation>
    <PMID>14828392</PMID>
  </reference>
  <reference>
    <citation>Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014 Jun;12(3):148-57. doi: 10.1016/j.surge.2013.12.001. Epub 2014 Mar 11. Review.</citation>
    <PMID>24629841</PMID>
  </reference>
  <reference>
    <citation>Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Löttgen J, Thiel A, Wienhard K, Heiss WD. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998 May;50(5):1316-22.</citation>
    <PMID>9595980</PMID>
  </reference>
  <reference>
    <citation>Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004 Nov 1;10(21):7163-70.</citation>
    <PMID>15534088</PMID>
  </reference>
  <reference>
    <citation>Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, Slart RH. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35. doi: 10.1007/s00259-012-2295-5. Epub 2012 Dec 12. Review.</citation>
    <PMID>23232505</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 31, 2016</lastchanged_date>
  <firstreceived_date>December 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Dongxiao Zhuang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <keyword>Methionine</keyword>
  <keyword>PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
